RESEARCH LETTER

Donor Estimated Glomerular Filtration Rate With or Without Body Surface Area Indexing and Kidney Transplant Graft Survival

To the Editor:

Assessing predonation glomerular filtration rate (GFR) is a key aspect in the evaluation of living kidney donor candidates. To determine eligibility for donation, international guidelines recommend determining estimated GFR (eGFR) and confirming adequate GFR using a second method, indexing all assessments for body surface area (BSA) because this indexing takes into account variations in donor size and, therefore, metabolic need-similar to the value of using BSA-adjusted eGFR in kidney disease staging.^{1,2} However, when predicting recipient outcomes, limited data suggest that donor GFR that is not BSAindexed provides a better estimate of the total clearance that will be provided by the allograft and therefore is a better indicator of living kidney donor quality.³ We compared the association of donor eGFR with versus without BSA indexing with post-transplant death-censored graft failure.

We identified adult US living donor kidney transplants 2000-2019 using Scientific Registry of Transplant Recipients data (n = 115,277) (see Acknowledgements). We excluded those missing donor predonation creatinine levels (n = 2,487) or with extremes of creatinine $(\leq 0.4 \text{ mg/dL}, n = 306; \geq 2.0 \text{ mg/dL}, n = 197)$. We then excluded those missing donor or recipient height or weight (n = 9,412). Finally, we excluded those with extremes of donor/recipient height (<120 cm, n = 142; >210 cm, n = 113) or weight (<40 kg, n = 515; >150 kg, n = 200) because most were suspected to be erroneous (eg, 20 donors with height < 61 cm [2 feet]). We calculated donor and recipient BSA using the DuBois formula.⁴ We calculated eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI 2021) formula⁵ and then removed the BSA indexing to determine deindexed eGFR as "dGFR" = $[eGFR \times BSA_{donor}/1.73 \text{ m}^2]$. We then recalculated eGFR after indexing for recipient BSA as "rGFR" = [dGFR × 1.73 m²/BSA_{recipient}]. We computed Cox proportional hazards models for death-censored graft failure separately with dGFR, eGFR, or rGFR as the independent variable, and calculated Harrell's C-index for each model. We then recalculated multivariable models adjusting for donor age, donor sex, recipient age, and recipient sex and calculated Harrell's C-index for each adjusted model. Finally, we calculated the subhazard of graft failure for each GFR estimated in Fine-Grey competing risk models treating death as a competing risk and then calculated the Akaike information criterion for each model. End of follow-up for each patient was last reported follow-up date or March

2, 2023 (end of file follow-up). Analyses used Stata/ MP17 (StataCorp, TX). This study was approved by the institutional review board of Columbia University Medical Center.

Among 101,905 donors included, the median BSA was 1.86 m^2 (interquartile range [IQR] 1.71-2.02, range 1.25-2.85). The median difference between donor and recipient BSA was -0.05 m^2 (IQR 0.26 to 0.16), including 0.02 m^2 (-0.14 to 0.17) for pairs of the same sex (Figure 1A) and -0.15 m^2 (-0.35 to 0.14) for pairs of opposite sex (Figure 1B). The median predonation dGFR was 111 mL/min (IQR 95-127) with a median eGFR of $104 \text{ mL/min}/1.73 \text{ m}^2$ (89-119), corresponding to a median difference of 7 (IQR -0.9 to 17) (Figure 1C and 1D). The median rGFR was $100 \text{ mL/min}/1.73 \text{ m}^2$ (IQR 84-118), with a median difference between eGFR and rGFR of 3 (-9 to 13).

When assessing the association of each GFR estimate with death-censored graft failure, 16,874 failures were observed. The Harrell's C-index was 0.525 for the model using dGFR (hazard ratio [HR] = 0.968 per 10 mL/min/1.73 m², 95% confidence interval [CI] 0.961-0.976, P < 0.001), 0.522 using eGFR (HR = 0.972 per 10 mL/min, 95% CI 0.967-0.979, P < 0.001), and 0.522 (HR = 0.974 per 10 mL/min/ 1.73 m^2 , 95% CI 0.968-0.980, P < 0.001) using rGFR. Results were similar when adjusting for donor and recipient age and sex (dGFR: Harrell's C-index = 0.604; eGFR: 0.605; rGFR: 0.608). Results were also similar when analyzing only transplants with donor BSA in the lowest or highest deciles of the group (dGFR: Harrell's C-index = 0.517; eGFR: 0.516; rGFR: 0.517). Finally, results were also similar in the full cohort when using a competing risk model with death as a competing risk AIC = 367, 678;eGFR: 367,680; (dGFR: rGFR: 367,700).

These results suggest that despite differences in BSAindexed and -deindexed predonation GFR estimates, removing living kidney donor BSA indexing from eGFR or re-indexing eGFR for recipient BSA did not strengthen the association between donor GFR and graft longevity. This finding may result from the low absolute difference in GFR estimates with versus without BSA indexing or may suggest that minor differences in living donor GFR do not have a large influence on posttransplant allograft survival. Additional limitations include that the impact of BSA indexing on allograft outcomes may be obscured by the fact that most transplant centers would be reluctant to use kidneys from donors that were much smaller than the intended recipient, thereby reducing potentially consequential instances of large BSA mismatches from appearing in transplant registries.

> Syed Ali Husain, MD, MPH, Kristen L. King, MPH, and Sumit Mohan, MD

Kidney Medicine



Figure 1. Body surface area (BSA) and predonation estimates of glomerular filtration rate (GFR) among living donor kidney transplants. (A, B) Recipient BSA versus donor BSA, where median difference between donor and recipient BSA was 0.02m² (IQR -0.14 to 0.17) for donor-recipient pairs of the same sex and -0.15 m² (IQR -0.35 to 0.14) for pairs of opposite sex. (C) Estimated GFR with BSA-indexing removed ("dGFR") versus estimated GFR with BSA-indexing ("eGFR"); the solid line shows the line of best fit, and the scored red line is the line of concordance. (D) The distribution of difference between dGFR and eGFR, where the median difference, as indicated by the vertical red line, was 7 (IQR -0.9 to 17).

ARTICLE INFORMATION

Authors' Affiliations: Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, NY (SAH, KLK, SM).

Address for Correspondence: Syed Ali Husain, MD, MPH, Division of Nephrology, Department of Medicine, 622 W 168th Street, PH4-124, New York, NY, USA, 10032. Email: sah2134@cumc.columbia. edu

Support: SAH was supported by a Nelson Family Faculty Development Award and NIDDK grant K23DK133729.

Financial Disclosure: The authors declare that they have no relevant financial interests.

Acknowledgements: This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donor, wait-listed candidates, and transplant recipients in the US, submitted by the members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors.

Data Sharing: The data reported here have been supplied by the Hennepin Healthcare Research Institute (HHRI) as the contractor for the Scientific Registry of Transplant Recipients (SRTR). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the SRTR or the US Government. The data underlying this article are available on request to the Scientific Registry of Transplant Recipients.

Peer Review: Received November 18, 2023. Evaluated by 1 external peer reviewer, with direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form February 23, 2024.

Publication Information: © 2024 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Published online July 26, 2024 with doi 10.1016/j.xkme.2024.100866

REFERENCES

 Lentine KL, Kasiske BL, Levey AS, et al. Summary of Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on the evaluation and care of living kidney donors. *Transplantation*. 2017;101(8):1783-1792.

Kidney Medicine

- 2. Levey AS, Inker LA. GFR evaluation in living kidney donor candidates. *J Am Soc Nephrol.* 2017;28(4):1062-1071.
- **3.** Norden G, Lennerling A, Nyberg G. Low absolute glomerular filtration rate in the living kidney donor: a risk factor for graft loss. *Transplantation*. 2000;70(9):1360-1362.
- 4. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. *Arch Intern Med.* 1916;17:863-871.
- Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. *N Engl J Med.* 2021;385(19):1737-1749.